NRAS and acute myeloid leukemia: Mutations in ASXL1, SRSF2, CBL, IDH2, EZH2, DNMT3A, NRAS and RUNX1 have been associated, in some of these studies, with poorer OS or increased risk of AML progression [6, 7, 11, 14, 15, 21–24].